Sanofi's Generics Business To Be Sold To Private Equity Firm, Advent
Sanofi will have €1.9bn to add to its war-chest when it concludes the sale of its European generics business.
You may also be interested in...
The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.
The private equity firms have agreed to pay more to Stada minority stockholders in a settlement that could add an extra €180-190m to their initial €5.4bn purchase price.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.